Introduction: Brimonidine tartrate is a lipid soluble alpha 2 adrenergic highly selective 
receptor agonist with potent vasoconstrictor activity that had been approved for management 
of open angle glaucoma, it is also currently indicated for the topical treatment of persistent 
(nontransient) facial erythema. Aim of the Work: The aim of the present study is to evaluate 
the use and effectiveness of topical brimonidine (alpha 2 adrenergic receptor agonist) 
clinically and histologically, for the management of facial erythema. Patients and Methods: 
The study was conducted on 20 patients presenting with red face. Cases were collected from 
those attending the dermatology outpatient clinic at Minia University Hospital in the period of 
July 2014 to April 2017. Results: The present study was conducted on 20 patients, attending 
the Dermatology outpatient clinic, Minia University Hospital for treating redness of face. The 
age of these patients at the time of the examination ranged from 12 to 55 years. Fourteen 
(60%) of them were female and six (40%) were males. Summary and Conclusions: The 
considerable desire of patients to have healthy skin and to get rid of any dermatologic 
problem is matched by the number of modalities offered to patients, both medically and nonmedically, to achieve that goal. Many of these modalities have been well studied, whereas 
others have not.